Health ❯ Healthcare ❯ Chronic Conditions

Obesity

Weight Management Treatment Options Type 2 Diabetes Health Risks Weight Regain Diabetes Cardiovascular Health Weight Loss Treatments Weight Loss Medications Treatment Strategies Hypertension Wegovy Weight Loss Injections Chronic Lung Disease Weight-Related Health Issues Dementia Economic Impact BMI and Health Conditions Osteoarthritis Long-term Treatment GLP-1 Medications Public Health Policy Management Strategies Comorbidities Weight-Related Comorbidities Associated Risks Weight Loss Strategies Medication Innovations GLP-1 Drugs Long-term Treatment Effects Heart Failure with Preserved Ejection Fraction Body Mass Index (BMI) Medications for Weight Loss Related Health Issues Market Trends Health Outcomes Medication Management BMI Monitoring Migraine Hypertension Relationship Associated Health Risks

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Novo Nordisk Slashes Wegovy Price in India by Up to 37% to Take On Mounjaro

Triple-Dose Semaglutide Outperforms Standard Regimen in Weight-Loss Trials

Bariatric Surgery Outperforms GLP-1 Medicines Over 10 Years for Patients With Diabetes and Obesity

Metformin Linked to Lower Dementia and Mortality Risks in Overweight, Obese Adults

GLP-1 Weight-Loss Drugs Fail to Boost Fitness and Cause Significant Muscle Loss

Liraglutide Cuts Chronic Migraine Days by More Than Half